BeBetter Med Appoints Dr. Congling Fu as CFO & CBO

Share Article

BeBetter Med announced today the appointment of Dr. Congling Fu as Chief Finance Officer & Chief Business Officer. In this role, Dr. Congling Fu will lead BeBetter’s finance, fund raising, IPO and business development. She will report to Dr. Changgeng Qian, CEO of BeBetter Med.

Dr. Fu has over 20-year experience in finance and business development. Prior to join BeBetter Med, she served as Managing Partner, China Head at Capvent AG, an early and growth stage investment fund based in Switzerland. She held managerial positions at Peregrine Investments, ABN AMRO Bank, and Pan-Pacific Investments. She was Director for Business Development and International Cooperation at the South China Center for Innovative Pharmaceuticals. Dr. Fu obtained a PhD from the University of Manchester in the UK and a MBA from INSEAD in France.

“I am pleased to join BeBetter Med, an innovative new drug company in China, which is widely recognized for its expertise in drug discovery and development,” said Dr. Fu. “I believe that my extensive experience gives me a unique perspective that will enable me to identify opportunities where BeBetter Med can deliver even greater value to shareholders, investors, partners, employees and society.”

“I am excited to welcome Congling (Connie) who is a seasoned leader in finance and business,” said Dr. Qian. “I look forward to working together as we further BeBetter’s new drug pipeline, plan for fund raising and IPO, and pursue international partnerships.”

About BeBetter Med
Guangzhou BeBetter Medicine Technology Co., LTD is a drug discovery and development company founded in 2012 by overseas returnees and aims to create advanced novel medicines to treat cancer and other challenging diseases. The company has strong expertise and outstanding facilities to conduct comprehensive pharmaceutical research from chemical synthesis to clinical evaluation. Several innovative drug candidates with own IP rights are entering IND filings and clinical trials. The company's leading anti-cancer drug candidate, BEBT-908, is expected to enter phase II clinical trial in China during the 2nd half of the year. To learn more, please visit http://www.bebettermed.com.

Contact:
Connie Fu Ph.D., MBA.
CFO & CBO
BeBetter Med Co, LTD.
25 Yayingshi Road, Science City
Guangzhou, China 510660
Phone: 86-20-3665-7220
Email: cfu@bebettermed.com

Share article on social media or email:

View article via:

Pdf Print